Small Cell Lung Cancer
Conditions
Keywords
small cell lung cancer
Brief summary
Clinical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future small cell lung cancer patients during clinical trials.
Interventions
None listed
Sponsors
Power Life Sciences Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. * Participant has a diagnosis of small cell lung cancer. * Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.
Exclusion criteria
* Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. * Pregnant or lactating woman * Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients who decide to enroll in a small cell lung cancer clinical study. | 3 months |
| Number of small cell lung cancer patients who remain in clinical trial until completion. | 12 months |
Contacts
Primary ContactMichael B Gill
Outcome results
None listed